Spruce Biosciences, Inc. SPRB
Set alert
46.39 USD -0.43 -0.92%
At close · Oct 30
46.39 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
44.69 Day range 46.62
38.98 52-week range 127.00
- YTD
- -46.75%
- 1 year
- -56.75%
- Open
- 46.11
- Prev close
- 46.82
- Mkt cap
- 133.33M
- Vol
- 65.96K
- Avg vol
- 81.10K
- EPS
- -39.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 44.69
- High
- 46.62
- Forward P/E
- -0.41
- Beta
- 0.00
- Short ratio
- 0.10
- Inst. own
- 46.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.50446
- 200-d avg
- 0.668845
- 1y target
- 1.83
5Y chart
Events in this range
- Mar 13, 2024Earnings: —; estimate -0.41; surprise —%
- May 13, 2024Earnings: -0.28; estimate -0.32; surprise 12.5%
- May 13, 2024Earnings: —; estimate -0.32; surprise —%
- Aug 12, 2024Earnings: -0.22; estimate -0.33; surprise 33.33%
- Aug 12, 2024Earnings: —; estimate -0.33; surprise —%
- Nov 11, 2024Earnings: -0.21; estimate -0.27; surprise 22.22%
- Nov 12, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 11, 2024Downgrade: Oppenheimer · Outperform → Perform
- Dec 11, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 11, 2024Downgrade: JMP Securities · Market Outperform → Market Perform
- Dec 12, 2024Rating: Guggenheim · Neutral → Neutral
- Dec 16, 2024Rating: HC Wainwright & Co. · Neutral → Neutral
- Aug 7, 2025Split: 1 for 75
Signals (65)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| RSI: Oversold | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 3, 2025 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bearish | Nov 18, 2024 | 1 year ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 22, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 18, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| RSI: Overbought | Feb 5, 2024 | 2 years ago |
| SMA: Bullish | Dec 18, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| RSI: Oversold | Oct 16, 2023 | 3 years ago |
| SMA: Bearish | Oct 2, 2023 | 3 years ago |
| SMA: Bearish | Sep 25, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 25, 2023 | 3 years ago |
| SMA: Bullish | Sep 11, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 11, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bearish | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Aug 21, 2023 | 3 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bullish | Jul 31, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 3, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| RSI: Overbought | Jan 23, 2023 | 3 years ago |
| RSI: Overbought | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 12, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 3, 2022 | 4 years ago |
| SMA: Bearish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Sep 5, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Apr 18, 2022 | 4 years ago |
| SMA: Bullish | Apr 11, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
| SMA: Bearish | Jan 10, 2022 | 4 years ago |
Key statistics
- Market cap
- 15.59M
- Enterprise value
- -40.58M
- Trailing P/E
- 0.00
- Forward P/E
- -0.41
- PEG ratio
- 0.00
- Price / sales
- 2.20
- Price / book
- 0.30
- EPS (TTM)
- -0.95
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.10M
- Revenue growth
- -80.40%
- Free cash flow
- -35.07M
- Total cash
- 60.05M
- Total debt
- 2.96M
- Return on equity
- -57.55%
- Shares outstanding
- 41.30M
- Short % of float
- 0.08%
- 50-day average
- 0.50446
- 200-day average
- 0.668845
Analyst view
Consensus: hold
Hold
Price target (mean) 1.83 -96.0% downside
Now 46.39
- Target (low)
- 1.00
- Target (mean)
- 1.83
- Target (high)
- 3.00
Ratings (0m) 5 0 buy · 5 hold · 0 sell
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.205.
Financials — quick view
SPRB Revenue — quarterly 0
SPRB Net income — quarterly -16.23M
SPRB EPS — quarterly -6.68
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.27 | -0.21 | +0.06 | +22.22% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | -0.22 | +0.11 | +33.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.32 | -0.28 | +0.04 | +12.50% |
| May 13, 2024 | Mar 1, 2024 | -0.32 | — | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Dec 12, 2024 | Guggenheim | reit | Neutral | Neutral |
| Dec 11, 2024 | JMP Securities | down | Market Outperform | Market Perform |
| Dec 11, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Dec 11, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 12, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sprucebiosciences.com
News
- Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target
- Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149
- Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B
- Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104
- Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144
- SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate
- B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160
- Spruce Biosciences Joins Russell 3000 Index, Effective June 29
- Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123
- Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135
Your note
Sign in to keep a note on SPRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARLTON RALPH WILLIAM III | Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 161,339 |
| GHARIB SAMIR M | President | Conversion of Exercise of derivative security | Dec 15, 2024 | 350,550 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 20, 2024 | 2,550,000 |
| O DONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| ODONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| SZWARCBERG JAVIER B M.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 467,191 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rivervest Venture Management LLC | 7.11% | 2,936,281 | 1.11M | Sep 29, 2024 |
| Carlyle Group Inc. | 7.01% | 2,896,518 | 1.09M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 6.32% | 2,609,125 | 984.94K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.05% | 1,259,151 | 475.33K | Sep 29, 2024 |
| Vanguard Group Inc | 2.04% | 843,844 | 318.55K | Sep 29, 2024 |
| Sands Capital Ventures, LLC | 1.91% | 787,007 | 297.10K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.55% | 638,558 | 241.06K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.48% | 197,187 | 74.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 153,228 | 57.84K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 40,000 | 15.10K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 36,510 | 13.78K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 31,503 | 11.89K | Oct 30, 2024 |